StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Each row shows where VRTX sits in our scored universe today on a single observational measurement. P85 means VRTX ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-22 | $437.07 | $434.52 | -0.58% | 1.7M |
| 05-26 | $437.99 | $435.93 | -0.47% | 0.9M |
| 05-27 | $438.52 | $437.22 | -0.30% | 1.2M |
| 05-28 | $434.08 | $447.97 | +3.20% | 1.4M |
| 05-29 | $448.01 | $447.54 | -0.10% | 1.9M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $2.99B | $12.00B | $8.81B | $5.73B |
Operating Income | $1.14B | $4.17B | $2.97B | $1.78B |
Net Income | $1.03B | $3.95B | $2.76B | $1.68B |
EPS (Diluted) | $4.02 | $15.32 | $10.68 | $6.48 |
Total Assets | $26.48B | $25.64B | $24.86B | $24.04B |
Total Liabilities | $7.12B | $6.98B | $7.54B | $6.86B |
Cash & Equivalents | $5.49B | $5.08B | $4.94B | $4.97B |
Free Cash Flow OCF − CapEx | $1.29B | $3.19B | $2.85B | $1.71B |
Shares Outstanding | 254.16M | 253.99M | 253.95M | 256.29M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.